— Why it moved
Why AEMD Stock Spiked and Faded Today — September 17, 2026
Aethlon Medical inked a reverse merger deal that hands away most of the company, but a tiny float triggered a brief premarket spike before the sell-off.
What moved AEMD stock
Aethlon Medical, Inc. develops immunotherapeutic technologies for cancer and infectious diseases. Early in the morning, the company announced an all-stock merger with North Immunology along with an $180 million private placement. Existing Aethlon shareholders will own just 4.75% of the combined entity once the transaction closes.
The mechanics
A microscopic float of 706,407 shares combined with a huge gap at the session's start created immediate volatility. More than 92 million shares rotated through the tape on a business that began the day valued under $1.1 million.
AEMD by the numbers
The alert window
The signal fired at 7:00 AM at $8.20. Anyone taking that trade immediately sat through a brutal 20.7% drawdown to $6.50 before the ticker pushed up to $9.83 at 9:21 AM. That offered a 19.9% sellable window before the market opened, but price held above the alert mark for a meager 34 minutes.
How AEMD's move ended
Sellers dominated the rest of the day, leaving the stock to close at $6.75 for a 17.7% loss from the alert price. The structural risk here is sheer dilution, as giving up 95% of the entity to incoming private placement investors leaves current equity holders with virtually nothing.
The tell: Reverse merger pops are almost always liquidity traps designed to shift ownership away from legacy retail holders.